Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

In this trial, both drugs helped improve these health markers, but tirzepatide’s added benefits could make it the top choice for many people with obesity. Still, not every patient will need the ...

Lilly’s Zepbound ® (tirzepatide) superior to Wegovy ® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Eli Lilly and Company.

Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 percent of their total body weight over the 72-week trial. SUBSCRIBE LOG IN ...

The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.

Lilly’s Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Lilly; December 4, 2024.

More than one-third of adults receiving tirzepatide in clinical trials experience gastrointestinal adverse events, but adverse events leading to drug discontinuation were rare, according to study ...

Two more phase 3 clinical trials of Eli Lilly’s tirzepatide in Type 2 diabetics have met their primary endpoints. The studies, like a trial that read out late last year, linked the dual GIP/GLP ...

Researchers collected data from the five SURPASS trials, which assessed the effects of tirzepatide among people with type 2 diabetes. Tirzepatide was compared with placebo in SURPASS-1 and SURPASS ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...